Ivan Hyep sold $301k of BCAX
Chief Financial Officer at Bicara Therapeutics Inc.. 16,518 shares at an average of $18.22, traded Mar 3, 2026, filed Mar 5, 2026.
Score components
- +22RoleCFO
- +14Trade size$301k at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +16.1%, 3m +10.3%, 6m +26.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-015421, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | MOption exercise Common Stock10b5-1 | +7,318 | $3.79 | $28k | 152,673 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Common Stock10b5-1 | +6,237 | $3.79 | $24k | 158,910 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -13,555 | $18.22 | $247k | 145,355 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock10b5-1 | +2,963 | $3.79 | $11k | 148,318 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,963 | $18.25 | $54k | 145,355 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,318 | $0.00 | $0 | 58,144 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,237 | $0.00 | $0 | 82,747 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,963 | $0.00 | $0 | 79,784 | Mar 5, 2026 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 18Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $525k 18,750 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $280k 10,000 shares | -3% | |
| 17Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $350k 12,500 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $284k 10,000 shares | -3% | |
| 29Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $808k 28,000 shares | -18% | |
| 28Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $833k 28,750 shares | -14% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $188k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $301k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $254k 12,500 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.